This site is intended for U.S. healthcare professionals only.

Request More Information About KENGREAL® (cangrelor)

If you would like to learn more about KENGREAL®, get updates when they become available, or have one of our sales representatives contact you, please fill out the fields below.

* Required field

By checking this box, you are giving Chiesi USA, Inc. permission to send or contact you with the information you have requested, as well as information and updates on KENGREAL® (cangrelor) or other Chiesi products in the future. Chiesi USA, Inc. will not sell or share any of your information with third parties.

Is this your email address?

Important Safety Information

KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

Please see full prescribing information.

This site is intended for U.S. healthcare professionals. If you are a U.S. healthcare professional, click OK to continue.